Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LXEO logo LXEO
Upturn stock rating
LXEO logo

Lexeo Therapeutics, Inc. Common Stock (LXEO)

Upturn stock rating
$9.6
Last Close (24-hour delay)
Profit since last BUY101.26%
upturn advisory
Consider higher Upturn Star rating
BUY since 56 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/21/2025: LXEO (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $19.78

1 Year Target Price $19.78

Analysts Price Target For last 52 week
$19.78 Target price
52w Low $1.45
Current$9.6
52w High $10.16

Analysis of Past Performance

Type Stock
Historic Profit 10.75%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/21/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 641.95M USD
Price to earnings Ratio -
1Y Target Price 19.78
Price to earnings Ratio -
1Y Target Price 19.78
Volume (30-day avg) 7
Beta -
52 Weeks Range 1.45 - 10.16
Updated Date 10/21/2025
52 Weeks Range 1.45 - 10.16
Updated Date 10/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.21

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -41.91%
Return on Equity (TTM) -75.32%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 237828133
Price to Sales(TTM) -
Enterprise Value 237828133
Price to Sales(TTM) -
Enterprise Value to Revenue 416.34
Enterprise Value to EBITDA -6.02
Shares Outstanding 69626214
Shares Floating 29333001
Shares Outstanding 69626214
Shares Floating 29333001
Percent Insiders 0.5
Percent Institutions 89.44

ai summary icon Upturn AI SWOT

Lexeo Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Lexeo Therapeutics is a clinical-stage gene therapy company focused on developing treatments for genetically defined cardiovascular and central nervous system diseases. Founded in 2021, it has rapidly advanced several programs into clinical trials.

business area logo Core Business Areas

  • Cardiovascular Gene Therapy: Developing gene therapy candidates for genetic cardiomyopathies such as dilated cardiomyopathy (DCM).
  • Central Nervous System (CNS) Gene Therapy: Developing gene therapy candidates for neurodegenerative diseases, including Alzheimer's disease.

leadership logo Leadership and Structure

The leadership team includes experienced biotechnology executives and scientific advisors. The company operates with a focus on research and development, clinical trials, and regulatory approval.

Top Products and Market Share

overview logo Key Offerings

  • LX2006 (DCM treatment): A gene therapy candidate for dilated cardiomyopathy caused by mutations in the LMNA gene. Phase 1/2 clinical trials are underway. Competitors include pharmaceutical companies developing traditional drug therapies for heart failure, as well as other gene therapy companies targeting cardiovascular diseases.
  • LX1001 (Alzheimer's treatment): A gene therapy candidate targeting APOE2 for the treatment of Alzheimer's disease. Phase 1/2 clinical trials are underway. Competitors include companies developing anti-amyloid antibodies (e.g., Biogen, Eli Lilly) and other Alzheimer's disease therapeutics.

Market Dynamics

industry overview logo Industry Overview

The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing success in clinical trials. The market is characterized by high development costs, regulatory hurdles, and significant unmet medical needs.

Positioning

Lexeo Therapeutics is positioned as a leader in developing gene therapies for cardiovascular and CNS diseases, focusing on genetically defined patient populations. Its competitive advantage lies in its proprietary gene therapy platform and experienced team.

Total Addressable Market (TAM)

The total addressable market for gene therapies in cardiovascular and CNS diseases is estimated to be in the billions of dollars. Lexeo is positioned to capture a significant share of this market with successful clinical trials and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Proprietary gene therapy platform
  • Experienced leadership team
  • Strong pipeline of clinical-stage programs
  • Focus on genetically defined patient populations
  • Strategic partnerships with leading academic institutions

Weaknesses

  • High development costs
  • Regulatory hurdles
  • Clinical trial risks
  • Dependence on external funding
  • Limited commercialization experience

Opportunities

  • Expansion of pipeline into new therapeutic areas
  • Strategic partnerships with pharmaceutical companies
  • Accelerated regulatory pathways for gene therapies
  • Increasing prevalence of genetic diseases
  • Positive clinical trial data

Threats

  • Competition from established pharmaceutical companies
  • Adverse clinical trial outcomes
  • Regulatory setbacks
  • Manufacturing challenges
  • Ethical concerns surrounding gene therapy

Competitors and Market Share

competitor logo Key Competitors

  • BLUE
  • CRSP
  • EDIT
  • VIR

Competitive Landscape

Lexeo faces competition from established pharmaceutical companies and other gene therapy developers. Its competitive advantage lies in its specific focus on genetically defined cardiovascular and CNS diseases and its proprietary gene therapy platform. The market share is estimated since LXEO is a small cap and does not hold as much market share as other competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily related to the advancement of clinical programs and fundraising activities.

Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of gene therapy products. Analyst estimates vary based on the perceived risk and potential of the company's pipeline.

Recent Initiatives: Recent initiatives include advancing clinical trials for LX2006 and LX1001, expanding the pipeline with new gene therapy candidates, and securing strategic partnerships.

Summary

Lexeo Therapeutics is a clinical-stage gene therapy company with a promising pipeline targeting significant unmet medical needs. The company's success hinges on positive clinical trial outcomes and regulatory approvals. High development costs and competition present challenges. Lexeo's targeted approach to genetically defined diseases could provide a competitive advantage if they can deliver strong efficacy results and have good safety profiles for their treatments. It is still an early stage company with much risk and high reward potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lexeo Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2023-11-03
CEO & Director Mr. R. Nolan Townsend
Sector Healthcare
Industry Biotechnology
Full time employees 61
Full time employees 61

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.